NICE Endorses Pegzilarginase for Treating Argin...

By HEOR Staff Writer

February 17, 2026

NICE Backs Pegzilarginase for Arginase Deficiency The National Institute for Health and Care Excellence (NICE) final draft guidance recommends pegzilarginase arginase deficiency trea...
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package
NICE Endorses Dupilumab for Eosinophilic COPD Treatment
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
Empowering Leaders at the Global Pharma Executive Course: Navigating Industry...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
Biomanufacturing Excellence Act: Strengthening U.S. Biopharmaceutical Manufac...
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Interchangeable Biosimilar Approval: FDA Greenlights Poherdy as First to Perjeta